Back to Search Start Over

Recent achievements in developing selective G q inhibitors.

Authors :
Zhang H
Nielsen AL
Strømgaard K
Source :
Medicinal research reviews [Med Res Rev] 2020 Jan; Vol. 40 (1), pp. 135-157. Date of Electronic Publication: 2019 Jun 19.
Publication Year :
2020

Abstract

G proteins are key mediators of G protein-coupled receptor (GPCR) signaling, facilitating a plethora of important physiological processes. The role of G proteins is much less understood than other aspects of GPCR function, which is largely due to the shortage of potent and selective G protein inhibitors. The natural cyclic depsipeptides YM-254890 and FR900359 are two of the very few known selective inhibitors of the G <subscript>q</subscript> subfamily, and are used as unique pharmacological tools in the study of G <subscript>q</subscript> -mediated signaling. Moreover, a peptide-based G protein antagonist-2A (GP-2A), a 27-residue peptide (27mer(I860A)) derived from phospholipase C-β3 (PLC-β3), and the small molecule BIM-46187 have also been characterized as selective G <subscript>q</subscript> inhibitors within the past 5 years. In this review, we highlight the recent development in chemical syntheses, characterization, and mechanism of action of these selective G <subscript>q</subscript> inhibitors. The development and application of G <subscript>q</subscript> -selective inhibitors will expand our knowledge of the structure and function of G protein-mediated signaling, shed light on the development of inhibitors for other G protein classes, and feed in to drug discovery for diseases where G proteins are implicated, including various forms of cancer.<br /> (© 2019 Wiley Periodicals, Inc.)

Details

Language :
English
ISSN :
1098-1128
Volume :
40
Issue :
1
Database :
MEDLINE
Journal :
Medicinal research reviews
Publication Type :
Academic Journal
Accession number :
31218731
Full Text :
https://doi.org/10.1002/med.21598